Amp Health: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://myamphealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Amp Health” on the pictured label, suggesting Amp Health is the compounder of those drugs when in fact it is not.”

2. 2

   “Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “The same active ingredient in Wegovy®*, Ozempic®*, and Saxenda®*” “Featuring the same active ingredient found in Mounjaro®* and Zepbound®*.””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

myamphealth.com returned HTTP 200 on 2026-08-09 but served a holding page titled "Maintenance Page - AmpHealth" reading "Website is under maintenance. We are doing some maintenance on our website to improve your experience", alongside promotional copy ("Get Your First Month of Weight Loss Medication for Free"). No catalogue, price or checkout was reachable. A maintenance page can precede a relaunch, so we record this as unknown rather than closed.

The asterisks are the whole story here. Somebody at this company had already decided the brand names needed a footnote — that is what an asterisk after Wegovy®* is for — and FDA quoted the asterisks and cited the copy anyway. The lesson for a reader is not that disclaimers are worthless; it is that a disclaimer attached to a comparison does not convert the comparison into an accurate one. If the sentence you are reading says a compounded product carries the same active ingredient as three branded drugs, the small print at the bottom of the page is not what determines whether that is a fair thing to tell you. There is a second, more practical point. This letter went to Dripgym Mobile Parent, LLC — a name that appears nowhere on the storefront and shares nothing with the domain. If you were trying to look up who you were buying from, the warning letter was the document that connected the three. Neither finding concerns the medicine's quality; both concern how much you could learn from the page before paying.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Amp Health failed to respond.